Partner Therapeutics secures FDA approval for Bizengri

Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or metastatic cholangiocarcinoma harbouring an NRG1 gene fusion and who have progressed on or after prior systemic therapy. The FDA approval was based on data from the multi-centre, open-label Phase II eNRGy clinical trial. Out of 22 patients with unresectable or metastatic NRG1+ cholangiocarcinoma, 19 were evaluable for efficacy. Credit: Gorodenkoff / Shutterstock.com. Partner Therapeutics has received the US Food and Drug Administration (FDA) approval for Bizengri (zenocutuzumab-zbco) to treat adults with advanced, unresectable or metastatic cholangiocarcinoma harbouring a neuregulin 1 (NRG1) gene fusion and who…

Source: Pharmaceutical Technology